FOLH1 and prostate carcinoma: To date, the most widely employed PSMA radioligand in clinical practice is 68Ga-PSMA-11 (also called 68Ga-DKFZ-PSMA-11 or 68Ga-PSMA-HBED-CC), developed by Eder and Haberkorn [10] and subsequently evaluated in clinical practice by Haberkorn and Afshar-Oromieh [11,12] at the German Cancer Research Centre in the University Hospital of Heidelberg, which consists of a Glu-urea-Lys inhibitor motif conjugated with Ga-specific acyclic chelator (HBED-CC) and shows higher affinity and internalization in prostate cancer cells than the corresponding DOTA analogue.